2025
Senescence Cell Induction Methods Display Diverse Metabolic Reprogramming and Reveal an Underpinning Serine/Taurine Reductive Metabolic Phenotype
Berardi D, Farrell G, AlSultan A, McCulloch A, Hall N, Sousa R, Jimenez M, Selman C, Bellantuono I, Johnson C, Rattray Z, Rattray N. Senescence Cell Induction Methods Display Diverse Metabolic Reprogramming and Reveal an Underpinning Serine/Taurine Reductive Metabolic Phenotype. Aging Cell 2025, e70127. PMID: 40530891, DOI: 10.1111/acel.70127.Peer-Reviewed Original ResearchSenescence inductionLabel-free proteomicsDNA damage markersRedox circuitsCell inductionImpaired proteostasisP21 levelsTherapeutic strategiesCellular phenotypesMetabolic phenotypeMetabolic reprogrammingProteomic heterogeneityMetabolic shiftSenescence markersProteomic profilingMetabolic processesSenescence biomarkersDamage markersProtein levelsSenescenceSubphenotypesSenescence modelInfluence cellsPhenotypeInductionEarly detection of lung injury and matrix metalloproteinase activation in ARDS could improve diagnostic and therapeutic strategies?
Cho S, Jang S, Heerdt P, Thorn S, Sinusas A. Early detection of lung injury and matrix metalloproteinase activation in ARDS could improve diagnostic and therapeutic strategies? Expert Review Of Respiratory Medicine 2025, ahead-of-print: 1-3. PMID: 40462542, DOI: 10.1080/17476348.2025.2515993.Peer-Reviewed Original ResearchMatrix metalloproteinase activityLung injuryTherapeutic strategiesMetalloproteinase activityEarly detectionFTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia
Huang H, Li X, Luo J, Gao C, Yang M, Xu J, Xie T, Chen Z, Wang D, Wang Y, Li H, Huang J, Liu Y, Zhang H, Ntziachristos P, Zhao Y, Qing G, Liu H. FTO regulates ELK3-mediated metabolic rewiring and represents a unique therapeutic target in T cell leukemia. Science Advances 2025, 11: eadq3052. PMID: 40435251, PMCID: PMC12118595, DOI: 10.1126/sciadv.adq3052.Peer-Reviewed Original ResearchConceptsT-cell leukemiaT-ALLT-cell acute lymphoblastic leukemiaAcute lymphoblastic leukemiaExpression of glycolytic genesDevelopment of potential therapeutic strategiesPotential therapeutic strategyAntileukemia efficacyLymphoblastic leukemiaLeukemia initiationLymphoid leukemiaTherapeutic strategiesGlycolytic genesPharmacological inhibitionMetabolic rewiringLeukemiaDemethylase FTOHuman cancersN6-methyladenosineMRNA stabilityTherapeutic targetCancerMechanistic analysisMRNAModel systemThe role of tight junctions in the pathogenesis of inflammatory bowel disease: immune modulation and barrier dysfunction
Heo J, Kim M, Yang Y, Choi H, Kim K, Oh T, Yang J, Kim Y, Park K. The role of tight junctions in the pathogenesis of inflammatory bowel disease: immune modulation and barrier dysfunction. Molecular & Cellular Toxicology 2025, 21: 495-506. DOI: 10.1007/s13273-025-00545-y.Peer-Reviewed Original ResearchInflammatory bowel diseaseIncreased epithelial permeabilityPathogenesis of inflammatory bowel diseaseBowel diseaseTight junctionsEpithelial permeabilityDisease progressionTherapeutic strategiesDisruption of tight junctionsRelease of proinflammatory cytokinesTumor necrosis factor-alphaPathophysiology of inflammatory bowel diseaseTight junction dysfunctionTight junction regulationTight junction disruptionTight junction integrityTight junction structureImmune cell activationMucosal immune systemRegulate paracellular transportNecrosis factor-alphaIntestinal tight junctionsInflammatory bowel disease managementNuclear factor kappa BInterleukin-1 betaSpatial-Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment.
Lv W, Zeng Y, Li C, Liang Y, Tao H, Zhu Y, Sui X, Li Y, Jiang S, Gao Q, Rodriguez-Fos E, Prasad G, Wang Y, Zhou R, Xu Z, Pan X, Chen L, Xiang X, Teng H, Sun C, Qin T, Dong W, Li Y, Lan X, Li X, Lin L, Bolund L, Yang H, Verhaak R, Faltas B, Hansen J, Wu S, Mischel P, Henssen A, Bafna V, Luebeck J, Regenberg B, Luo Y, Lin C, Han P. Spatial-Temporal Diversity of Extrachromosomal DNA Shapes Urothelial Carcinoma Evolution and the Tumor Immune Microenvironment. Cancer Discovery 2025, of1-of22. PMID: 40331621, DOI: 10.1158/2159-8290.cd-24-1532.Peer-Reviewed Original ResearchTraumatic Vertebral Artery Injury: Diagnosis, Natural History, and Key Considerations for Management
Teasdale B, Owolo E, Padmanaban V, Elsamadicy A, Amllay A, Shankar G, Krieger P, Regenhardt R, Hebert R, Stapleton C, Rabinov J, Matouk C, Patel A, Sujijantarat N. Traumatic Vertebral Artery Injury: Diagnosis, Natural History, and Key Considerations for Management. Journal Of Clinical Medicine 2025, 14: 3159. PMID: 40364191, PMCID: PMC12072270, DOI: 10.3390/jcm14093159.Peer-Reviewed Original ResearchVertebral artery injuryBlunt cervical spine traumaRisk of vertebral artery injuryNatural historyCervical spine traumaVertebral artery occlusionPotential risk of strokeRisk of strokeComprehensive narrative reviewCo-existing injuriesCervical traumaSpine traumaSpinal cord injuryIntracranial hemorrhageIschemic sequelaeEndovascular managementAntiplatelet therapySurgical interventionRecanalization rateArterial injuryArtery occlusionIncreased riskTherapeutic strategiesDiagnostic approachBony injuriesCardiomyocyte-specific NHE1 overexpression confers protection against myocardial infarction during hyperglycemia
Jiang K, Su F, Deng R, Xu Y, Qin A, Yuan X, Xing D, Chen Y, Wang D, Shen L, Hwa J, Hou L, Xiang Y. Cardiomyocyte-specific NHE1 overexpression confers protection against myocardial infarction during hyperglycemia. Cardiovascular Diabetology 2025, 24: 184. PMID: 40287728, PMCID: PMC12034198, DOI: 10.1186/s12933-025-02743-3.Peer-Reviewed Original ResearchConceptsNa+/H+ exchanger 1Na+/H+ exchanger 1 activationAcute hyperglycemiaMyocardial infarctionNHE1 overexpressionNHE1 activityTherapeutic strategiesCardiomyocyte necroptosisHistory of diabetes mellitusReduced extracellular Na+Worsened cardiac dysfunctionRetrospective cohort studyDouble knockout miceIschemia-reperfusion modelNon-diabetic individualsPost-MI patientsReduced infarct sizePathophysiology of MIBackgroundAcute hyperglycemiaElevated BNPMLKL knockoutReduced cardiomyocyte deathAcute myocardial infarctionExtracellular Na+Intracellular Na+Sex differences in cerebrospinal fluid proteomics of patients with restless legs syndrome
Mogavero M, Peng G, Marchese G, Lanza G, Ferini-Strambi L, Ferri R, Koo B. Sex differences in cerebrospinal fluid proteomics of patients with restless legs syndrome. Sleep 2025, zsaf112. PMID: 40289925, DOI: 10.1093/sleep/zsaf112.Peer-Reviewed Original ResearchRestless legs syndromeProteomic signatureCerebrospinal fluid proteomeUntreated RLS patientsObservational cross-sectional studyBody mass indexProteome of patientsCerebrospinal fluid samplesSex-specific mechanismsCross-sectional studyRLS patientsSex-specific analysesMass indexSex differencesTherapeutic strategiesImmune responseInflammatory pathwaysEffective treatmentCerebrospinal fluid proteome of patientsDisease pathophysiologyPatientsSyndromeProtein levelsFluid samplesProteomic alterationsThe shifting landscape of the preterm brain
Kratimenos P, Sanidas G, Simonti G, Byrd C, Gallo V. The shifting landscape of the preterm brain. Neuron 2025 PMID: 40239653, DOI: 10.1016/j.neuron.2025.03.024.Peer-Reviewed Original ResearchPreterm infantsGestational ageLong-term outcomes of preterm infantsLong-term neurodevelopmental consequencesOutcomes of preterm infantsPreterm brain injuryLong-term outcomesPreterm birth complicationsInvestigate therapeutic strategiesPreterm brainPreterm birthHypoxia-ischemiaIntracranial hemorrhageNeonatal careImpaired brain functionGlobal health concernPretermBirth complicationsOligodendrocyte injuryNon-pharmacological approachesUtero developmentTherapeutic strategiesSurvival rateInfantsBirth persistGene editing using CRISPR-Cas9 technology: potential implications in assisted reproduction
Sahin G, Seli E. Gene editing using CRISPR-Cas9 technology: potential implications in assisted reproduction. Current Opinion In Obstetrics & Gynecology 2025, 37: 141-148. PMID: 40232991, DOI: 10.1097/gco.0000000000001022.Peer-Reviewed Original ResearchConceptsNonhomologous end joiningHomology-directed repairCRISPR-Cas9 technologyReproductive biologyGenome editingAnalysis of epigenetic mechanismsAssisted reproductionMitochondrial genome editingHuman assisted reproductionMitigate off-target effectsNovel therapeutic strategiesGene function studiesDCas9 systemFertility genesHereditary disorderHuman infertilityGenome modificationTherapeutic strategiesAnimal modelsGene activationHereditary mutationsEpigenetic modificationsEnd joiningGenetic mutationsEpigenetic mechanismsThe diversity of CD8+ T cell dysfunction in cancer and viral infection
Galluzzi L, Smith K, Liston A, Garg A. The diversity of CD8+ T cell dysfunction in cancer and viral infection. Nature Reviews Immunology 2025, 1-18. PMID: 40216888, DOI: 10.1038/s41577-025-01161-6.Peer-Reviewed Original ResearchChronic viral infectionsCD8+ T cellsViral infectionT cellsCD8+ T cell dysfunctionT cell dysfunctionClinical management of cancerChronically infected cellsManagement of cancerAntigenic stimulationClinical managementHypofunctional stateTherapeutic strategiesInfectionCancerInfected cellsCell deathPathological scenariosPrevent exhaustionCD8AnergyCellsNeoplasmsHypofunctionDysfunctionFluid Shear Stress–Regulated Vascular Remodeling: Past, Present, and Future
Deng H, Eichmann A, Schwartz M. Fluid Shear Stress–Regulated Vascular Remodeling: Past, Present, and Future. Arteriosclerosis Thrombosis And Vascular Biology 2025, 45: 882-900. PMID: 40207366, PMCID: PMC12094896, DOI: 10.1161/atvbaha.125.322557.Peer-Reviewed Original ResearchConceptsFluid shear stressShear stressVascular remodelingVascular bedCapillary densityOutward remodelingIn vivo animal modelsPotential therapeutic interventionsDownstream vascular bedArterial toneTherapeutic strategiesAnimal modelsPerfusion of tissuesAdequate perfusionUpstream arteriesEndothelial cellsVascular diseaseBlood flowTherapeutic interventionsClinical implicationsBlood vesselsTreat vascular diseasesFlowMetabolic stressBloodSynergistic Antibacterial Effects of Plant Extracts and Essential Oils Against Drug-Resistant Bacteria of Clinical Interest
Shahin H, Baroudi M, Dabboussi F, Ismail B, Salma R, Osman M, Omari K. Synergistic Antibacterial Effects of Plant Extracts and Essential Oils Against Drug-Resistant Bacteria of Clinical Interest. Pathogens 2025, 14: 348. PMID: 40333114, PMCID: PMC12030331, DOI: 10.3390/pathogens14040348.Peer-Reviewed Original ResearchConceptsFractional inhibitory concentration indexAntibacterial effect of plant extractsListeria monocytogenes</i>Drug-resistant bacteriaDrug-resistant microorganismsEmergence of drug-resistant microorganismsSynergistic antibacterial effectCombat antimicrobial resistanceMicrodilution assayBacterial strainsCombination of essential oilsAntibacterial efficacyTested essential oilsAntimicrobial resistanceEssential oilEffects of plant extractsCrude extractEucalyptus globulus</i>Treated with antimicrobialsAntibacterial effectPlant extractsAntibioticsTherapeutic strategiesAlternative therapiesClinical interestPLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid Leukemia
Sheth A, Chan K, Liu S, Wan J, Angus S, Rhodes S, Mitchell D, Davis C, Ridinger M, Croucher P, Zeidan A, Wijeratne A, Qian S, Tran N, Potchanant E. PLK1 Inhibition Induces Synthetic Lethality in Fanconi Anemia Pathway–Deficient Acute Myeloid Leukemia. Cancer Research Communications 2025, 5: 648-667. PMID: 40111122, PMCID: PMC12011380, DOI: 10.1158/2767-9764.crc-24-0260.Peer-Reviewed Original ResearchConceptsAcute myeloid leukemiaSporadic acute myeloid leukemiasMyeloid leukemiaOS of AMLMitotic centromeresPathway mutationsFA pathway-deficient cellsLack of predictive biomarkersPlk1 inhibitionFanconi anemiaSurvival of acute myeloid leukemiaPlk1 inhibitorsIdentification of patientsSynthetic lethal therapeutic strategyMitotic kinase Plk1Tumor suppression networkOverall survivalPredictive biomarkersClinical successPatient populationKinase Plk1Mitotic chromosomesTherapeutic strategiesMitotic collapseSynthetic lethalityModerate alcohol-associated hepatitis: A real-world multicenter study
Idalsoaga F, Díaz L, Dunn W, Mehta H, Muñoz K, Caldentey V, Arnold J, Ayares G, Mortuza R, Sarin S, Maiwall R, Zhang W, Qian S, Simonetto D, Singal A, Elfeki M, Ramirez-Cadiz C, Malhi G, Ahmed A, Homsi H, Abid Z, Cabezas J, Echavarría V, Poca M, Soriano G, Cuyas B, Cots M, La Tijera M, Ayala-Valverde M, Perez D, Gomez J, Abraldes J, Al-Karaghouli M, Jalal P, Ibrahim M, García-Tsao G, Goyes D, Skladaný L, Havaj D, Sulejova K, Selcanova S, Rincón D, Chacko K, Restrepo J, Yaquich P, Toro L, Shah V, Arrese M, Kamath P, Bataller R, Arab J. Moderate alcohol-associated hepatitis: A real-world multicenter study. Hepatology Communications 2025, 9: e0673. PMID: 40131003, PMCID: PMC11936654, DOI: 10.1097/hc9.0000000000000673.Peer-Reviewed Original ResearchConceptsSevere alcohol-associated hepatitisNeutrophil-to-lymphocyte ratioMaddrey's discriminant functionModerate AHMultiple organ failureOrgan failureMulticenter retrospective cohort studyAlcohol-associated hepatitisCumulative survival rateRetrospective cohort studyReceiver operating characteristic curveLong-term outcomesShort-term mortalityMortality scoring systemsPrognostic factorsSerum bilirubinMELD scoreWell-characterized diseaseClinical profileMedian MELDCohort studyCox regressionMultivariate analysisTherapeutic strategiesSurvival rateTargeting FKBP51 prevents stress-induced preterm birth
Guzeloglu-Kayisli O, Ozmen A, Un B, Un B, Blas J, Johnson I, Thurman A, Walters M, Friend D, Kayisli U, Lockwood C. Targeting FKBP51 prevents stress-induced preterm birth. EMBO Molecular Medicine 2025, 17: 775-796. PMID: 40097636, PMCID: PMC11982339, DOI: 10.1038/s44321-025-00211-9.Peer-Reviewed Original ResearchConceptsDecidual stromal cellsPreterm birthProgesterone receptorFKBP51 levelsIdiopathic preterm birthPrevent preterm birthMaternal-fetal interfaceFDA-approved therapiesExpression of FKBP5Activity of glucocorticoidsPerinatal morbidityShortened gestationPR receptorsInitiate laborTranscriptional activity of glucocorticoidProlonged gestationStress-related disordersTherapeutic strategiesStromal cellsInhibit transcriptional activationCo-treatmentPTGS2 levelsMaternal stressGestationFKBP51The Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications—A Narrative Review
Mahabamunuge J, Sekula N, Lepore C, Kudrimoti M, Upadhyay A, Alshowaikh K, Li H, Seifer D, AlAshqar A. The Molecular Basis of Polycystic Ovary Syndrome and Its Cardiometabolic Correlates: Exploring the Intersection and Its Clinical Implications—A Narrative Review. Biomedicines 2025, 13: 709. PMID: 40149685, PMCID: PMC11940587, DOI: 10.3390/biomedicines13030709.Peer-Reviewed Original ResearchPolycystic ovary syndromeType 2 diabetes mellitusCardiometabolic morbidityIncreased cardiovascular riskDevelopment of hypertensionCardiovascular risk factorsNarrative reviewPotential clinical implicationsAndrogen excessEndothelial dysfunctionCardiovascular riskClinical conditionsPredisposed individualsTherapeutic strategiesAdipokine secretionRisk factorsInsulin resistanceCardiometabolic diseasesCardiovascular diseaseClinical implicationsMorbidityMellitusSyndromeMolecular mechanismsDiseasePrecision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC
Nousias O, Mandell J, Anderson K, Townsend J. Precision projections of the delay of resistance mutations in non-small cell lung cancer via suppression of APOBEC. Lung Cancer 2025, 202: 108487. PMID: 40090261, DOI: 10.1016/j.lungcan.2025.108487.Peer-Reviewed Original ResearchNon-small cell lung cancer patientsNon-small cell lung cancerCell lung cancer patientsCell lung cancerLung cancer patientsEvolution of drug resistanceLung cancerDrug resistanceCancer patientsTyrosine kinase inhibitor therapyKinase inhibitor therapyTyrosine kinase inhibitorsPersonalized therapeutic strategiesTKI therapyInhibitor therapyTherapeutic failureResistance mutationsTherapeutic efficacyKinase inhibitorsAPOBEC mutationsTherapeutic strategiesTreatment efficacyCancer progressionImprove outcomesCancerCardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis
Hammer M, Tysarowski M, Fuss C, Bader A. Cardiac Magnetic Resonance Imaging in Immune Checkpoint Inhibitor–Related Myocarditis. Echocardiography 2025, 42: e70131. PMID: 40067334, DOI: 10.1111/echo.70131.Peer-Reviewed Original ResearchConceptsImmune-related adverse eventsImmune checkpoint inhibitorsCardiac magnetic resonance imagingMagnetic resonance imagingAssociated with immune-related adverse eventsCardiac immune-related adverse eventsMechanisms of immune checkpoint inhibitorsICI-associated myocarditisICI-related myocarditisResonance imagingPersonalized cancer immunotherapySevere cardiovascular complicationsImmune tolerance pathwayCheckpoint inhibitorsCancer immunotherapyCardiac complicationsCombination therapyTumor cytotoxicityClinical presentationCardiovascular complicationsAdverse eventsTherapeutic efficacyOncological treatmentTherapeutic strategiesMyocarditisAn antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy
Schrank B, Wang Y, Wu A, Tran N, Lee D, Edwards J, Huntoon K, Dong S, Ha J, Ma Y, Grippin A, Jeong S, Antony A, Chang M, Kang M, Gallup T, Koong A, Li J, Yun K, Kim B, Jiang W. An antibody–toxin conjugate targeting CD47 linked to the bacterial toxin listeriolysin O for cancer immunotherapy. Nature Cancer 2025, 6: 511-527. PMID: 40000910, PMCID: PMC11952976, DOI: 10.1038/s43018-025-00919-0.Peer-Reviewed Original ResearchConceptsAntibody-toxin conjugatesTumor cellsImmune recognition of tumor cellsEnhanced antigen cross-presentationRecognition of tumor cellsCancer cell phagocytosisTumor-derived antigensToxin listeriolysin OTumor-derived peptidesImproved animal survivalPromote immune recognitionCytosolic immune sensorsIntracellular bacterium Listeria monocytogenesTreatment in vivoTreating multiple cancersPhagocytosis checkpointsCheckpoint blockadeCancer immunotherapySignal CD47Listeriolysin OMetastatic breastMelanoma tumorsTherapeutic strategiesAnimal survivalCell phagocytosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply